Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Early Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07214532
What this trial is testing

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Who this might be right for
Breast NeoplasmsCarcinoma, Ductal, BreastReceptors, Estrogen (for ER-positive Requirement)
Natera, Inc. 725
Not applicableStudy completedNCT07561346
What this trial is testing

Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer

Who this might be right for
HER2-zero, HER2-low and HER2-positive Tumors Distribution Across HR Expression Categories
Hellenic Cooperative Oncology Group 3,648
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07047755
What this trial is testing

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Who this might be right for
Breast Cancer
Henan Cancer Hospital 48
Testing effectiveness (Phase 2)Study completedNCT00943670
What this trial is testing

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 51
Large-scale testing (Phase 3)Active Not RecruitingNCT05346224
What this trial is testing

Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHER2-positive Breast Cancer
Shanghai Henlius Biotech 900
Not applicableUnknownNCT05734950
What this trial is testing

Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer

Who this might be right for
Breast Cancer Female
Royal Marsden NHS Foundation Trust 100
Testing effectiveness (Phase 2)Study completedNCT03112590
What this trial is testing

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast CancerBreast Cancer, MaleBreast Cancer Female+1 more
H. Lee Moffitt Cancer Center and Research Institute 51
Not applicableUnknownNCT03947242
What this trial is testing

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.

Who this might be right for
HER2 Positive Breast Cancer
Henan Cancer Hospital 48
Not applicableStudy completedNCT01959386
What this trial is testing

Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 1,006
Testing effectiveness (Phase 2)Study completedNCT00475670
What this trial is testing

Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 44
Not applicableNot Yet RecruitingNCT07521202
What this trial is testing

IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE

Who this might be right for
HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit 257
Testing effectiveness (Phase 2)Study completedNCT03644186
What this trial is testing

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

Who this might be right for
Breast CancerEstrogen Receptor Positive TumorHER2-positive Breast Cancer
ETOP IBCSG Partners Foundation 147
Not applicableLooking for participantsNCT07527741
What this trial is testing

Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

Who this might be right for
Early-stage HER2+ Breast Cancer
Hoffmann-La Roche 100
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Large-scale testing (Phase 3)Study completedNCT02125344
What this trial is testing

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Who this might be right for
Tubular Breast Cancer Stage IITubular Breast Cancer Stage IIIMucinous Breast Cancer Stage II+4 more
GBG Forschungs GmbH 961
Testing effectiveness (Phase 2)UnknownNCT05945368
What this trial is testing

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

Who this might be right for
HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 78
Testing effectiveness (Phase 2)Study completedNCT01827163
What this trial is testing

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Who this might be right for
HER2-Positive Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center 20
Not applicableLooking for participantsNCT07484087
What this trial is testing

Ablation Compare With Surgery for Early Breast Cancer

Who this might be right for
Breast CancerEarly StageHormone Receptor Positive+1 more
Peking University People's Hospital 264
Large-scale testing (Phase 3)Study completedNCT03556358
What this trial is testing

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsHER2-positive Breast Cancer+2 more
Tanvex BioPharma USA, Inc. 809
Not applicableStudy completedNCT01152606
What this trial is testing

Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin

Who this might be right for
Breast Cancer
Hoffmann-La Roche 3,942
Next Page